Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Clinical trial NCT04401709 · UNKNOWN

Trial details

NCT number: NCT04401709
Sponsor: Samsung Medical Center
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Biliary Tract Cancer

Start date: 2021-04-01
Primary completion: 2025-03-30
Enrollment: 490

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.